EA200500606A1 - Пептиды, модулирующие активацию каспазы - Google Patents
Пептиды, модулирующие активацию каспазыInfo
- Publication number
- EA200500606A1 EA200500606A1 EA200500606A EA200500606A EA200500606A1 EA 200500606 A1 EA200500606 A1 EA 200500606A1 EA 200500606 A EA200500606 A EA 200500606A EA 200500606 A EA200500606 A EA 200500606A EA 200500606 A1 EA200500606 A1 EA 200500606A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- peptides
- asp
- alpha
- fetoprotein
- caspase activation
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 102000011727 Caspases Human genes 0.000 title abstract 2
- 108010076667 Caspases Proteins 0.000 title abstract 2
- 230000004913 activation Effects 0.000 title abstract 2
- 102100023635 Alpha-fetoprotein Human genes 0.000 abstract 3
- 108010026331 alpha-Fetoproteins Proteins 0.000 abstract 3
- 230000006907 apoptotic process Effects 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 2
- 102100027211 Albumin Human genes 0.000 abstract 1
- 108010088751 Albumins Proteins 0.000 abstract 1
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102000018832 Cytochromes Human genes 0.000 abstract 1
- 108010052832 Cytochromes Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 210000004748 cultured cell Anatomy 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 208000033065 inborn errors of immunity Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000037353 metabolic pathway Effects 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000036542 oxidative stress Effects 0.000 abstract 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Abstract
Настоящее изобретение раскрывает структуры небольших молекул, способных к модуляции апоптотической гибели клетки. В частности, структуры относятся к структурам апоптотически активных участков альфа-фетопротеина (AFP) и альбумина млекопитающих. Пептиды, имитирующие активный участок, содержат две последовательности Arg-Gly-Asp и Asp-X-X-Asp, в которой Х обозначает любую аминокислоту. Данные последовательности необходимы в той же самой молекуле для того, чтобы вызвать широкий диапазон биологической активности. Пептиды можно использовать для того, чтобы подавить апототические метаболические пути, ингибируя опосредованную цитохромом С активацию каспазы. Таким образом, пептиды можно использовать для того, чтобы ингибировать эффекты апоптоза, вызванного окислительным стрессом, лекарственными средствами, цитокинами, лигандами Fas, альфа-фетопротеином, используемым для предотвращения апоптоза в культивирующихся клетках, в органах для трансплантации, при иммунологических аутоиммунных нарушениях и синдроме иммунодефицита, вызванном вирусной инфекцией, или для уменьшения побочных цитотоксических эффектов после химиотерапии и лучевой терапии.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20021798A FI118263B (fi) | 2002-10-09 | 2002-10-09 | Kaspaasiaktiivisuutta säätelevät peptidit |
| PCT/FI2003/000735 WO2004033500A1 (en) | 2002-10-09 | 2003-10-07 | Peptides modulating caspase activation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200500606A1 true EA200500606A1 (ru) | 2006-06-30 |
| EA010058B1 EA010058B1 (ru) | 2008-06-30 |
Family
ID=8564726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200500606A EA010058B1 (ru) | 2002-10-09 | 2003-10-07 | Пептиды, модулирующие активацию каспазы |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7446095B2 (ru) |
| EP (1) | EP1558649B1 (ru) |
| JP (1) | JP4446121B2 (ru) |
| CN (1) | CN100551930C (ru) |
| AT (1) | ATE470677T1 (ru) |
| AU (1) | AU2003271784A1 (ru) |
| DE (1) | DE60332950D1 (ru) |
| DK (1) | DK1558649T3 (ru) |
| EA (1) | EA010058B1 (ru) |
| ES (1) | ES2347234T3 (ru) |
| FI (1) | FI118263B (ru) |
| PT (1) | PT1558649E (ru) |
| WO (1) | WO2004033500A1 (ru) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2444105A4 (en) * | 2009-06-16 | 2013-08-21 | Univ Tokai | GRAM NEGATIVE ANTI-BACTERIAL AGENT |
| CN101812448B (zh) * | 2010-01-15 | 2011-12-07 | 浙江大学 | 一种肝癌靶向双重组凋亡蛋白表达序列及应用 |
| CN102060913B (zh) * | 2010-11-30 | 2012-09-05 | 暨南大学 | 一种与人血清白蛋白结合的七肽与应用 |
| US10238690B2 (en) | 2013-03-15 | 2019-03-26 | Celgene Corporation | Modified T lymphocytes comprising an inducible caspase and methods of apoptosis |
| CN108186666B (zh) * | 2018-01-29 | 2020-02-21 | 西北大学 | 一种dna纳米带在抗细胞凋亡上的应用及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1226551B (it) * | 1988-07-29 | 1991-01-24 | Sclavo Spa | Peptide sintetico immunologicamente attivo capace di indurre la produzione di anticorpi con elevata specificita' verso l'alfa- fetoproteina e loro impiego in campo diagnostico |
| EP0805687A4 (en) | 1995-01-24 | 2000-05-31 | Robert A Murgita | ALPHA-F RECOMBINANT HUMAN TOPROTEIN AND USES THEREOF |
| WO1998010792A1 (en) * | 1996-09-11 | 1998-03-19 | Prendergast Patrick T | Immune direction therapy |
| CN1739791A (zh) * | 1997-02-13 | 2006-03-01 | 加利福尼亚大学董事会 | 肝细胞癌的预防及治疗 |
| AU7104500A (en) * | 1999-09-02 | 2001-03-26 | Atlantic Biopharmaceuticals, Inc. | Use of rafp to inhibit or prevent apoptosis |
| ATE494301T1 (de) * | 2001-06-02 | 2011-01-15 | Clf Medical Technology Acceleration Program Inc | Alpha-fetoprotein-peptide und ihre verwendung |
-
2002
- 2002-10-09 FI FI20021798A patent/FI118263B/fi active IP Right Grant
-
2003
- 2003-10-07 AU AU2003271784A patent/AU2003271784A1/en not_active Abandoned
- 2003-10-07 AT AT03753618T patent/ATE470677T1/de active
- 2003-10-07 ES ES03753618T patent/ES2347234T3/es not_active Expired - Lifetime
- 2003-10-07 PT PT03753618T patent/PT1558649E/pt unknown
- 2003-10-07 JP JP2004542524A patent/JP4446121B2/ja not_active Expired - Fee Related
- 2003-10-07 EP EP03753618A patent/EP1558649B1/en not_active Expired - Lifetime
- 2003-10-07 EA EA200500606A patent/EA010058B1/ru not_active IP Right Cessation
- 2003-10-07 US US10/530,779 patent/US7446095B2/en not_active Expired - Fee Related
- 2003-10-07 DE DE60332950T patent/DE60332950D1/de not_active Expired - Lifetime
- 2003-10-07 CN CNB2003801011658A patent/CN100551930C/zh not_active Expired - Fee Related
- 2003-10-07 DK DK03753618.2T patent/DK1558649T3/da active
- 2003-10-07 WO PCT/FI2003/000735 patent/WO2004033500A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| FI118263B (fi) | 2007-09-14 |
| DK1558649T3 (da) | 2010-10-11 |
| ES2347234T3 (es) | 2010-10-27 |
| EA010058B1 (ru) | 2008-06-30 |
| CN1703428A (zh) | 2005-11-30 |
| CN100551930C (zh) | 2009-10-21 |
| WO2004033500A1 (en) | 2004-04-22 |
| US7446095B2 (en) | 2008-11-04 |
| PT1558649E (pt) | 2010-09-14 |
| ATE470677T1 (de) | 2010-06-15 |
| AU2003271784A1 (en) | 2004-05-04 |
| FI20021798A (fi) | 2004-04-10 |
| JP2006518703A (ja) | 2006-08-17 |
| EP1558649A1 (en) | 2005-08-03 |
| EP1558649B1 (en) | 2010-06-09 |
| US20060280732A1 (en) | 2006-12-14 |
| DE60332950D1 (de) | 2010-07-22 |
| JP4446121B2 (ja) | 2010-04-07 |
| FI20021798A0 (fi) | 2002-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Karle et al. | Peptide hybrids containing α-and β-amino acids: Structure of a decapeptide β-hairpin with two facing β-phenylalanine residues | |
| Nagaike et al. | Efficient microwave-assisted tandem N-to S-acyl transfer and thioester exchange for the preparation of a glycosylated peptide thioester | |
| Thind et al. | Mechanisms of myocardial ischemia–reperfusion injury and the cytoprotective role of minocycline: scope and limitations | |
| ES2721172T3 (es) | Una nueva clase de moléculas terapéuticas a base de proteínas | |
| Buckton et al. | Improving the cell permeability of polar cyclic peptides by replacing residues with alkylated amino acids, asparagines, and d-amino acids | |
| AR024699A1 (es) | Polipeptidos hibridos con propiedades farmacocineticas aumentadas | |
| AR051765A1 (es) | Compuestos de moleculas conjugadas con una actividad reforzada de absorcion de celulas | |
| EA200500606A1 (ru) | Пептиды, модулирующие активацию каспазы | |
| EA200500420A1 (ru) | Бензолсульфонатные соли производных 4-фтор-2-цианопирролидина | |
| WO2007009019A3 (en) | Protein compositions for promoting wound healing and skin regeneration | |
| RU2018118985A (ru) | Комбинированные лекарственные средства, содержащие модуляторы pkm2 и hmgb1 | |
| Jiang et al. | Design and synthesis of redox stable analogues of sunflower trypsin inhibitors (SFTI-1) on solid support, potent inhibitors of matriptase | |
| DE602006014140D1 (de) | Mit scytovirin der domäne 1 verwandte polypeptide | |
| Kuncewicz et al. | BTLA-derived peptides as inhibitors of BTLA/HVEM complex formation–design, synthesis and biological evaluation | |
| RU2011110711A (ru) | Новые биологически активные пептиды и их новое применение | |
| DK1551977T3 (da) | Selektiv, lokal aktivering af medlemmer af TNF-ligand-familien af systemisk inaktive ikke-antistof-TNF-ligand-fusionsproteiner | |
| DK1204679T3 (da) | Peptider som indeholder N-substituerede D-aminosyrer til at forhindre associering af Beta-strenge | |
| Zhao et al. | Design, Preparation of 3‐Hydroxy Isoindolinone Cyclotripeptides, and the In Vitro Antitumor Activities Against Cervical Carcinoma HeLa Cells | |
| RU2001125031A (ru) | Пептид, обладающий противоопухолевой, протекторной и нормализующей активностью, и фармацевтическая композиция | |
| Blondelle | Understanding Biology Using Peptides: Proceedings of the Nineteenth American Peptide Symposium | |
| Bajaj et al. | Introduction of histidine units using benzotriazolide activation | |
| EA200401611A1 (ru) | Пептиды gp41 и способы ингибирования слияния вич с клетками-мишенями на их основе | |
| Verardo et al. | Characterization of N‐Boc/Fmoc/Z‐N′‐formyl‐gem‐diaminoalkyl derivatives using electrospray ionization multi‐stage mass spectrometry | |
| Ueki et al. | Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms | |
| BR112023027305A2 (pt) | Variante de interleucina-15, conjugado, proteína de fusão, ácido nucleico, vetor, célula hospedeira e composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1A | Registration of transfer to a eurasian application by force of assignment | ||
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): KZ MD TJ TM |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |